Vangipuram Rangan
About Vangipuram Rangan
Vangipuram Rangan serves as the Executive Director of Protein Sciences at CytomX Therapeutics, where he has worked since 2021. He has over three decades of experience in biochemistry and protein therapeutics, including significant roles at Bristol-Myers Squibb and Children's Hospital Oakland Research Institute.
Current Role at CytomX Therapeutics
Vangipuram Rangan serves as the Executive Director of Protein Sciences at CytomX Therapeutics, a position he has held since 2021. In this role, he oversees the development of therapeutic antibodies and antibody-drug conjugates (ADCs). Rangan functions as a liaison between the Discovery and Development groups, ensuring effective collaboration on therapeutic programs. His work contributes to advancing CytomX's mission in the field of protein sciences.
Previous Experience at Bristol-Myers Squibb
Prior to his current role, Rangan worked at Bristol-Myers Squibb as Senior Director of Protein Chemistry from 2009 to 2018. During his nine years there, he focused on biologics discovery, contributing to the development of various therapeutic candidates. His experience at Bristol-Myers Squibb helped shape his expertise in protein chemistry and biologics development.
Career at Children's Hospital Oakland Research Institute
Rangan began his career at the Children's Hospital Oakland Research Institute, where he served as an Associate Scientist from 1989 to 2001. Over the course of twelve years, he gained foundational experience in research and development, which contributed to his later roles in the biopharmaceutical industry.
Education and Expertise in Biochemistry
Rangan earned his PhD in Biochemistry from the University of Mysore, where he studied from 1983 to 1988. His educational background provides a solid foundation for his extensive experience in protein sciences, including the development and implementation of analytical strategies for preclinical biologics development. He is skilled in evaluating and collaborating with contract research organizations (CROs) and contract manufacturing organizations (CMOs).
Achievements in Therapeutic Development
Throughout his career, Rangan has successfully transitioned more than 15 antibody therapeutics and 3 ADCs from discovery to Investigational New Drug (IND) applications. Notably, he contributed to the development of Opdivo, an approved drug that has had a significant impact in the field of oncology. His expertise includes writing standard operating procedures (SOPs) and protein chemistry sections for IND filings.